Literature DB >> 9627367

Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects.

V A Fonseca1, S Mudaliar, B Schmidt, L M Fink, P A Kern, R R Henry.   

Abstract

An association between hyperhomocysteinemia and premature atherosclerosis in patients with non-insulin-dependent diabetes mellitus (NIDDM) has recently been described. Little is known about the role of insulin in homocysteine [H(e)] metabolism. We measured plasma H(e) concentrations in the fasting state and during a hyperinsulinemic-euglycemic clamp in normal subjects and patients with NIDDM. Plasma H(e) decreased significantly from 7.2 +/- 2.6 to 6.0 +/- 2.7 mmol/L (P < .01) in normal subjects, but did not change in patients with NIDDM (6.0 +/- 2.7 to 5.9 +/- 2.5 mmol/L, respectively). These data suggest that plasma H(e) concentrations are regulated by acute hyperinsulinemia in normal subjects, but not in insulin-resistant NIDDM subjects. These abnormalities may have implications for the pathogenesis of premature vascular disease associated with NIDDM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9627367     DOI: 10.1016/s0026-0495(98)90031-2

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  14 in total

1.  Mild hyperhomocysteinemia and the common C677T polymorphism of methylene tetrahydrofolate reductase gene are not associated with the metabolic syndrome in Type 2 diabetes.

Authors:  G T Russo; A Di Benedetto; E Alessi; R Ientile; A Antico; G Nicocia; R La Scala; E Di Cesare; G Raimondo; D Cucinotta
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

2.  Homocysteine, folate, lipid profile and MTHFR genotype and disability in children with myelomeningocele.

Authors:  Claudia Rendeli; Emanuele Ausili; Mario Castorina; Daniela Antuzzi; Fabrizia Tabacco; Massimo Caldarelli
Journal:  Childs Nerv Syst       Date:  2006-04-07       Impact factor: 1.475

3.  Plasma homocysteine and lipoprotein (a) levels in Turkish patients with metabolic syndrome.

Authors:  Aytekin Guven; Fatma Inanc; Metin Kilinc; Hasan Ekerbicer
Journal:  Heart Vessels       Date:  2005-11       Impact factor: 2.037

Review 4.  Drugs affecting homocysteine metabolism: impact on cardiovascular risk.

Authors:  Cyrus Desouza; Mary Keebler; Dennis B McNamara; Vivian Fonseca
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics.

Authors:  Mabrouka El Oudi; Zied Aouni; Haroun Ouertani; Chakib Mazigh; Salem Machghoul
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

6.  Menopause modulates homocysteine levels in diabetic and non-diabetic women.

Authors:  G T Russo; A Di Benedetto; E Alessi; A Giandalia; A Gaudio; R Ientile; K V Horvath; B Asztalos; G Raimondo; D Cucinotta
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

Review 7.  Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis.

Authors:  Pierre Theuma; Vivian A Fonseca
Journal:  Curr Diab Rep       Date:  2003-06       Impact factor: 4.810

8.  Elevation of fasting insulin and its association with cardiovascular disease risk in women with systemic lupus erythematosus.

Authors:  Tim K Tso; Wen-Nan Huang
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

9.  Effect of zinc supplementation on serum homocysteine in type 2 diabetic patients with microalbuminuria.

Authors:  Esfandiar Heidarian; Massoud Amini; Mahmoud Parham; Ashraf Aminorroaya
Journal:  Rev Diabet Stud       Date:  2009-05-10

10.  Age and kidney function are the primary correlates of fasting plasma total homocysteine levels in non-diabetic and diabetic adults. Results from the 1999-2002 National Health and Nutrition Examination Survey.

Authors:  Glen E Duncan; Sierra M Li; Xiao-Hua Zhou
Journal:  Nutr Metab (Lond)       Date:  2005-05-26       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.